<DOC>
	<DOCNO>NCT01623466</DOCNO>
	<brief_summary>Pharmacokinetics , safety wearability two size patch AG890 eight week evaluate .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics Profile , Wearability , Safety 2 Progestin-Only Patches</brief_title>
	<detailed_description />
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Body mass index ( BMI ) great equal 18 . Willing use nonhormonal method contraception childbearing potential , already undergone previous bilateral tubal ligation hysterectomy Willing refrain excessive use alcohol 48 hour prior patch application completion study . Known suspect pregnancy Lactating woman Status postpartum postabortion within period 2 month prior start study medication A cervical cytology smear Papanicolaou ( Pap ) class III great Bethesda System report low grade squamous intraepithelial lesion ( SIL ) great Smoking Hypertension ( blood pressure &gt; 140 mm Hg systolic and/or &gt; 90 mm Hg diastolic ) Valvular heart disease complication ECG ( woman BMI â‰¥35 kg/m2 ) clinically significant finding Diabetes Mellitus History headaches focal neurological symptom Uncontrolled thyroid disorder Sickle cell anemia Current history clinically significant depression last year Known disturbance lipid metabolism Acute chronic hepatocellular disease abnormal liver function Hepatic adenoma carcinoma Cholestatic jaundice pregnancy jaundice prior hormonal contraceptive use Plans major surgery History exist venous arterial thrombotic thromboembolic disorder , vascular disease , cerebral vascular , coronary artery disease Undiagnosed abnormal genital bleed Known suspect breast carcinoma , endometrial carcinoma , estrogendependent neoplasia History presence dermal hypersensitivity response topical application ( bandage , surgical tape , etc . ) Use injectable hormonal contraceptive within past 10 month prior screen visit Use contraceptive implant hormonemedicated intrauterine device ( IUD ) within 1 month prior screen visit Use oral contraceptive sex steroid hormone within 2 month prior screen visit Chronic use medication might interfere efficacy hormone contraceptive ( include barbiturate , bosentan , carbamazepine , felbamate , griseofulvin , oxcarbazepine , phenytoin , rifampin , St. John 's Wort , topiramate , HIV protease inhibitor ) , OR use medication within past 3 month prior screen visit A recent history ( within prior 2 year ) drug alcohol abuse</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>PK Safety</keyword>
</DOC>